Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Journal of Hematology & Oncology volume 14, Article number: 135 (2021)
Correction to: J Hematol Oncol (2021) 14:121 https://doi.org/10.1186/s13045-021-01111-4
The original article  incorrectly states that OMO-1 is a MYC inhibitor in two instances: in the Direct MYC Inhibition sub-section of the MYC Inhibitors section, and in Table 3.
The authors wish to clarify that OMO-1 is not a MYC inhibitor, and its mentions in the original article should be disregarded.
Ahmadi SE, et al. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol. 2021;14:121. https://doi.org/10.1186/s13045-021-01111-4.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ahmadi, S.E., Rahimi, S., Zarandi, B. et al. Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 14, 135 (2021). https://doi.org/10.1186/s13045-021-01152-9